Aurobindo Pharma shares dipped 2.14% to ₹1,666.50 on the BSE after the company disclosed Acrotech Biopharma’s ADQUEY launch.
ADQUEY is a topical ointment that blocks phosphodiesterase‑4, designed for mild‑to‑moderate atopic dermatitis in adults and children aged two and older. The drug enters the U.S. market as the first non‑steroidal option in a space dominated by steroid creams and a few biologics.
IQVIA estimates the U.S. dermatology market to reach roughly $1.3 billion for the 12 months ending July 2026, a figure that dwarfs the niche segment ADQUEY occupies but signals ample upside for a differentiated therapy. Compared with last year’s $820 million market, the sector is growing at a 15.4% CAGR, positioning new entrants like ADQUEY to capture market share quickly.
Ashish Anvekar, president of Acrotech Biopharma, said the launch marks a milestone: “We are building a dedicated dermatology platform that will not only support ADQUEY today but also pave the way for future specialty drugs.” The company has set up a dedicated business unit with marketing, sales and field‑based teams, a move that signals long‑term commitment beyond a single product launch.
Looking ahead, Acrotech plans to broaden its dermatology pipeline, with several candidates in early development stages. The company will also monitor regulatory pathways for potential approvals in adjacent indications such as psoriasis. Analysts expect the launch to lift the company’s valuation modestly, but market reception will hinge on real‑world efficacy data and competitive pricing strategies.